XenoPort Inc.’s chief executive steps down as part of a broader restructuring that will eliminate about 25 jobs as the biopharmaceutical company focuses on its treatment for restless leg syndrome, the company said Thursday.
read more
XenoPort Inc.’s chief executive steps down as part of a broader restructuring that will eliminate about 25 jobs as the biopharmaceutical company focuses on its treatment for restless leg syndrome, the company said Thursday.
read more